Introduction
Prostate cancer (PCa) has the highest incidence of all solid tumors in Europe, which is estimated to be >200 cases per 100,000 men [1] . It is a major health problem concern, especially in developed countries with a greater proportion of elderly men in the general population. Metastatic prostate cancers at diagnosis occur in less than 10% of patients in developed countries [2] . In less developed countries, metastatic disease is the most common presentation of PCa, which represents an important public health issue. In recent years, the median survival of patients with newly diagnosed metastases was 42 months [3] .
Over 70 years ago, Huggins and Hodges as well as Niehans demonstrated the responsiveness of symptomatic metastatic PCa to castration. Androgen deprivation therapy (ADT) is the current standard of care in first-line metastatic setting [4] . Before new active drugs were introduced, median survival with ADT varied from 31 to 49 months [5] . However, the outcome of this treatment varies widely and resistance to ADT occurs in most patients.
Median duration of sensitivity to ADT is usually 24-36 months [6] . In patients with resistance to ADT, docetaxel plus prednisone therapy resulted in a median survival that was approximately 2.5 months longer than that with mitoxantrone and prednisone [7] .
Three randomized controlled trials were conducted at an earlier stage, in patients with hormone-sensitive metastatic PCa, comparing ADT alone as a standard to an experimental arm combining ADT with upfront docetaxel [8] . These trials reported findings regarding survival benefits that are not all statistically significant. In order to discuss these results, 16 French specialists in onco-urology, including urologists, radiation therapists and medical oncologists, worked together. The aim of this work was to present the evidence from the literature and the remaining questions regarding the benefit of early chemotherapy in patients with hormone-sensitive metastatic PCa. This article is summarizing their work.
Results from the published trials comparing ADT alone to ADT plus docetaxel in hormonesensitive metastatic PCa Three randomized controlled trials were conducted in patients with hormone-sensitive metastatic PCa, comparing ADT alone as a standard to an experimental arm combining ADT with upfront docetaxel. For these 3 trials, there was no blinding to treatment allocation and the primary endpoint was overall survival. non-significant 20% reduction in the risk of death in the high-volume disease subgroup was found, but patients with low-volume disease had no survival improvement with early docetaxel.
GETUG-AFU 15 trial (NCT00104715)

CHAARTED trial (NCT00309985)
The design of this trial was substantially the same as GETUG-AFU 15, but the patients were supposed to receive 6 cycles of docetaxel (whithout daily prednisone) instead of 10 [11] . The study was initially designed for patients with high-risk disease, defined as PCa with visceral metastases or more than 3 bone metastases with at least 1 appendicular localization.
Secondarily, patients with low-volume disease were also included, due to difficulties for recruitment. As a consequence, patients with low-volume had a shorter follow-up. 
Meta-analysis and discrepancies between reported trials
A meta-analysis of these three trials was performed and confirmed the overall survival improvement by adding upfront docetaxel to ADT in hormone-sensitive metastatic PCa [13] .
Assuming a typical 4-year survival with standard of care of 40%, the meta-analysis HR of 0.77 (95% CI: 0.68-0.87; p<0.0001), translates to a 9% (95% CI: 5-14) absolute improvement with standard of care plus docetaxel compared to standard of care alone.
However, there are some discrepancies between the populations included in the 3 trials (Table 1 As a consequence, although data from the literature provides substantial and reliable evidence that adding docetaxel to standard of care improves the survival of men with hormone-sensitive metastatic disease, several questions remain before this treatment is offered to all men who are fit to receive chemotherapy.
Role of docetaxel in patients with low-volume disease
No predictive factors are currently available to identify which patient will benefit from the upfront chemotherapy-ADT combination. However, volume of metastases could possibly be a relevant predictive factor. The definition of high-volume disease used in the CHAARTED trial was a combination of features from prior classifications. All the definitions included the presence of visceral disease as a predictor of poor prognosis. According to the definition of the South-West Oncology Group, any lesion beyond the vertebrae and pelvis, irrespective of total lesion count, would be classified as "extensive" [14] . In the CHAARTED trial, the site of bone metastases combined with the number of metastases was considered to avoid classifying patients with four or fewer metastases as having high-volume disease, even if one lesion was beyond the vertebrae and pelvis.
In the subgroup of patients with high-volume disease, the median OS was 17 months longer in the combination group than in the ADT-alone group (49.2 months vs. 32.2 months). In contrast, median OS was not significantly different (HR=0.60; 95% CI: 0.32-1.13; p=0.11) in patients with low-volume disease. However, the median survival had not been reached at the time of the analysis. Furthermore, the inclusion of patients with low-volume disease was only allowed at a late stage of the inclusion (in order to speed up recruitment) and thus the follow-up of these patients was much shorter than for the high volume subgroup.
In the STAMPEDE trial, the survival benefit is clear in metastatic subpopulation, which accounted for 61% of patients in the trial. But the volume of metastases was not considered as a criterion for subgroup analysis.
In the post-hoc analysis of GETUG-AFU 15, patients with high-volume disease had a median OS improvement of 4.7 months in the ADT plus Docetaxel arm, but the difference was not statistically significant as compared to the ADT arm: 39.8 months (95% CI: 28.0-53.4) versus 35.1 months (95% CI: 29.9-43.6) (HR=0.78; 95% CI: 0.56-1.09; p=0.14) ( Table 2 ). The lack of significant OS benefit with ADT plus docetaxel in patients with high volume disease in GETUG-AFU15, despite a significant improvement in biochemical and radiological progression-free survival may thus have resulted of 2 combined phenomenon: a much lower median OS with ADT plus docetaxel as compared to CHAARTED (39.8 months versus 49.2 months) and a slightly better median OS in the ADT arm (35.1 months versus 32.2 months).
Since both studies had a similar design, several hypotheses have been proposed to explain these discrepancies. First, the CHAARTED study included twice as many patients as the GETUG-AFU 15 study, leading to possible insufficient power for the GETUG-AFU15 trial to demonstrate a benefit of chemotherapy. Second, patients in the CHAARTED trial had worse prognosis and, were perhaps more likely to gain benefits from chemotherapy: 64% and 66% and sipuleucel-T (9.2% and 6.6%) ( Table 3) . Taken together, this indicates that patients in the experimental arm received life-extending drugs more frequently, either at randomization (Docetaxel) or beyond progression, than patients in the control arm. In the GETUG-AFU15 study, the vast majority of patients (85%) in the ADT arm received so-called salvage Docetaxel within a median time of 18.5 months (95% CI, 2.9-179) while only 48% of patients received salvage docetaxel in CHAARTED trial. The percentage of patients receiving other life-extending treatments (abiraterone, enzalutamide, and cabazitaxel) beyond progression in ADT arm was rather similar between GETUG-AFU 15 and CHAARTED. The much higher use of salvage docetaxel in the ADT arm of GETUG-AFU 15 (85%) as compared to CHAARTED (48%) and STAMPEDE (41%) may contribute to explain the better performance of GETUG-AFU 15 ADT arm (Table 2 ) [15] .
Gleason score and chemotherapy benefit
Subgroup analysis using prognostic factors like Gleason score, showed that there was a benefit of ADT + Docetaxel versus ADT whatever the Gleason score. Surprisingly, it seems that the benefit of docetaxel in survival is more important for patients with Gleason score ≤ 7. These results are remarkable in CHAARTED and there is a trend in both GETUG-AFU 15
and STAMPEDE, even if there is a lack of specific data for the metastatic patients in these last trials. This trend was also found in earlier stage in the GETU-AFU 12 study [16] . The explanation for this effect remains unknown. However, it seems important to have a centralized histologic analyze with dedicated uro-pathologist to prevent mis-interpretation.
Influence of local treatment
In all three randomized trials, most of the men who were randomly assigned to treatment groups were newly diagnosed with metastatic disease, but patients initially treated for local disease could also be included. In the GETU-AFU 15 trial, these patients represented 28% of cases, and had a significantly longer survival (83.1 vs 46.5 months; HR=1.57; 95% CI: 1.09-2.26; p=0.015). But no significant difference in OS was observed between treatment arms (ADT plus Docetaxel vs ADT) between patients with de novo and secondary metastatic diseases. In the CHAARTED study, 27% had previous local treatment and there was no benefit to docetaxel in this subgroup population (HR=0.55; 95% IC: 0.23-1.31; p>0.05). These patients usually have a good follow-up and the metastatic progression is more commonly diagnosed at an earlier stage. For this population, the benefit of Docetaxel and ADT combination is less obvious.
Association of prednisone with docetaxel
In the three trials of docetaxel in hormone-sensitive metastatic PCa, prednisone was not coadministrated with docetaxel except in the STAMPEDE study (prednisone 10mg/day).
In patients with androgen deprivation therapy, it is supposed that low dose of prednisone could influence fatigue, nausea and the number of circulating granulocytes. Furthermore, multiple studies have confirmed an effect on PSA levels [17] . In a recent retrospective study of 358 patients, co-administration of low-dose prednisone reduced the incidence of peripheral edema, grade 3 non-hematologic toxicity and the risk of being admitted owing to febrile neutropenia during treatment with docetaxel [18] . Adjusted survival analysis did not indicate the prednisone affected prognosis. However, the patients included had metastatic castration-resistant PCa.
Furthermore, prednisone can affect the clearance of docetaxel, it can hide the manifestations of febrile neutropenia and it has long-term effects on osteoporosis. There was no obvious benefit in terms of febrile neutropenia (12% in STAMPEDE versus 6-8% in GETUG-AFU 15 and CHAARTED) in the three trials. As a consequence, prednisone doesn't seem to be useful in association with docetaxel in hormone-sensitive setting.
What is the optimal number of cycles of docetaxel in hormone-sensitive metastatic PCa?
It seems that the standard in hormone-sensitive metastatic PCa is 6 cycles of docetaxel. This was the design of the randomized trials, except for GETUG-AFU 15 with 10 cycles initially planned and a median of 9 cycles administrated.
Adverse effects of chemotherapy and patients' self-assessment
Across the three trials, the number of reported grade 3-4 adverse events increased with docetaxel, most commonly neutropenia. In the meta-analysis of Vale et al., 16 deaths were attributed to docetaxel, including 4 in the GETUG-AFU 15, in the early experience of docetaxel use. Data from the GETUG-AFU 15 study showed that adverse events after docetaxel treatment should be closely monitored, and the frequency of severe neutropenia should be limited by granulocyte colony-stimulating factor. Before the amendment of the study protocol to allow administration of granulocyte colony-stimulating factor, grade 3-5 neutropenia was noted in almost a third of patients, 7% of patients had febrile neutropenia, and two patients died from neutropenia-related conditions. However, after the amendment, the frequency of neutropenia and febrile neutropenia of grade 3-4 decreased substantially and no subsequent toxic deaths occurred.
In the CHAARTED trial, approximately 6% of the patients in the combination group had neutropenic fever, and approximately 2% had grade 3 or 4 infection with neutropenia. In the STAMPEDE study, febrile neutropenia occurred in up to 15% in the arm SOC + Docetaxel.
Febrile neutropenia after docetaxel treatment was more frequent in these studies than in previous.
One explanation could be that docetaxel clearance is increased by about 100% in men with castration-resistant PCa compared with those with non-castrate disease, and is associated with a two-fold reduction in the area under the curve, although hepatic activity of cytochrome P450 3A4 is unchanged (p=0.0001), probably because of an increase in hepatocyte uptake [19] . This is concordant with the results of TAX 327 with 3% of febrile neutropenia in patients with castration resistant metastatic PCa [7] .
However, physicians should keep in mind that they often fail to report symptoms of cancer treatment toxicity, even the most common and disturbing ones [20] . Patients are the best source of information about their own symptoms and a self-assessment of toxicity would improve patient's care and consequently medical outcome. Consequently, the continuation of chemotherapy should be carefully evaluated.
Data about patient's quality of life were only published in the GETUG-AFU 15 trial: quality of life was altered during chemotherapy, but it improved rapidly at the end of the treatment, except for constipation. The quality of life should be taken into account, and the balance between duration of toxicity and survival without progression seems to be in favor of chemotherapy in high-volume disease. Qol analysis of the phase III CHAARTED study was 
Docetaxel in elderly patients
Age is often considered a limitation to the administration of docetaxel. The oncogeriatric evaluation of the patient is of high importance, and practical tools like the onco-G8 score are now available to detect patients who would benefit from comprehensive geriatric assessment [21] .
In a subgroup analysis of the TAX327 study, the survival improvement with 3-weekly docetaxel compared with mitoxantrone was similar for patients aged 68 years or younger and those older than 68 years (hazard ratios 0·81 vs 0·77, not significantly different) [22] .
In a retrospective analysis of patients aged 75 years or older treated with docetaxel (either 3-weekly or weekly regimen according to clinical judgment), patients with a good performance status showed responses similar to those of younger patients, and it was generally well tolerated [23] . In both CHAARTED and STAMPEDE, there was a benefit for docetaxel whatever the age. However, in most studies, patients are highly selected which can differ from real life practice [24] .
Surveillance and early detection of progression
The surveillance of the patients under treatment is an important issue that can influence the outcome. Close radiological and biological monitoring could result in increasing the number of treatment lines, which might be associated with better overall survival [25] . Clinical indications for the use of imaging in PCa depend on the different phase of the disease. have demonstrated the utility 11C-choline PET/CT to assess the response to docetaxel in 61 patients with metastatic PCa, with a greater role for progressive disease [27] . These results are preliminary and future prospective studies are needed to assess the role of radiolabeled PET/CT as a tool for early response assessment to chemotherapy. Alternative PET tracers, like PSMA, are promising, although there are not yet available in many countries [28] .
A close follow-up of the patients under treatment is important to early detect the nonresponding-patients but also to prevent side effects and medical interactions in this population of patients with frequent comorbidities. Currently no data are available on how patients should be followed after ADT-docetaxel exposure for hormone-sensitive metastatic PCa.
Post-docetaxel treatments and cross-resistance
There is currently no evidence in the literature to define the best treatment option after progression after first line of docetaxel + ADT. Several criteria may influence the choice of the second line of treatment: interval between the end of treatment and progression, symptomatology and quality of life of the patient as well as toxicity experience of the previous treatment. In the literature, new hormone therapies (abiraterone, enzalutamide) [29] and chemotherapy (cabazitaxel) [30] have proven an overall survival benefit in metastatic castration-resistant PCa progressing after docetaxel. But there is no data available in the setting of progression after chemotherapy in hormone-sensitive metastatic PCa.
Data from basic research support the development of cancer as an ongoing Darwinian evolutionary process, leading to multiple competing subclones within the primary tumor but also in the metastases [31] . Recently, polyclonal seeding and interclonal cooperation among different metastases in the context of androgen deprived metastatic PCa has been reported [32] . Metastasis to metastasis spread was found to be common, either through de novo monoclonal seeding of daughter metastases or through the transfer of multiple tumor clones between metastatic sites.
The current strategy in metastatic PCa is sequential: after failing to respond optimally to one This will be a good opportunity to evaluate its association to the new hormonotherapies, with or without local treatment.
Conclusion
Data from the literature provide substantial and reliable evidence on the benefit of adding docetaxel to ADT in hormone-sensitive metastatic PCa. However, there are still no predictive factors to identify the best candidates and optimum time for chemotherapy. The level of evidence to support a benefit of docetaxel in high-volume disease is high. Since PCa is a very early heterogeneous disease, it is hypothesized that chemotherapy plus ADT would work in both situations. Consequently, there is an urgent need to identify clinical and/or molecular predictive factor in order to help physician to take the best treatment decision. Other trials will provide information on the use of docetaxel in even earlier stages of the disease, and also on the best options after docetaxel exposure. The paradigm shift lies in the fact that physicians have to deal with several effective therapeutic options for metastatic PCa. The combination of these treatments, including new hormonotherapies, might be the next step forward. 
